ArticlemAbs2016

Preclinical studies of a Pro-antibody-drug conjugate designed to selectively target EGFR-overexpressing tumors with improved therapeutic efficacy.

Yun Yang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.